Want to see HK:2591 full AI Analyst Report?
Top Page
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H
(2591)
Select Model
Select Model
Rating:45Neutral
Price Target:
HK$3.50
▼(-50.70% Downside)
Action:Reiterated
Date:09/22/26
The score is held down primarily by persistent large operating losses and continued negative operating/free cash flow despite the 2025 revenue ramp and strong gross margin. Technicals add additional pressure given the downtrend versus longer-term moving averages and negative MACD. Valuation contributes only modestly because the negative P/E reflects ongoing losses and there is no dividend yield to offset risk.
Positive Factors
Revenue Inflection and Gross Margin
The 2025 revenue inflection establishes a commercial base where none was reported previously, while the strong gross margin indicates substantial economics on reported sales. If revenue continues scaling, this combination could provide operating leverage and support a path toward improved profitability.
Negative Factors
Persistent Large Operating Losses
Large operating and net losses show that the current cost base remains far ahead of revenue generation, despite the strong gross margin on reported sales. Until revenue scales materially or expenses are reduced, the business lacks a dependable earnings engine and remains exposed to prolonged profitability risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Inflection and Gross Margin
The 2025 revenue inflection establishes a commercial base where none was reported previously, while the strong gross margin indicates substantial economics on reported sales. If revenue continues scaling, this combination could provide operating leverage and support a path toward improved profitability.
Read all positive factors
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H (2591) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.55B
Dividend YieldN/A
Average Volume (3M)5.97M
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue Growth182.60%
EPS Growth-48.01%
CountryHK
Employees214
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding420,285,370
10 Day Avg. Volume3,961,080
30 Day Avg. Volume5,969,855
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)11.34
Price to Sales (P/S)93.25
P/FCF Ratio-37.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H Business Overview & Revenue Model
Company Description
Guangzhou Innogen Pharmaceutical Group Co Ltd operates as a China-based investment holding firm with a core mission to research, develop, and bring to market medicinal products. The company specializes in producing innovative, human-compatible, an...
How the Company Makes Money
null...
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
64
Positive
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 150.95M | 128.11M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 114.74M | 104.43M | -17.28M | -19.65M | -19.08M |
| EBITDA | -318.34M | -323.92M | -156.89M | -711.42M | -308.37M |
| Net Income | -329.11M | -332.53M | -174.69M | -733.38M | -306.99M |
Balance Sheet | |||||
| Total Assets | 1.30B | 1.57B | 934.80M | 1.11B | 668.71M |
| Cash, Cash Equivalents and Short-Term Investments | 1.02B | 1.21B | 796.88M | 945.34M | 501.37M |
| Total Debt | 151.19M | 166.33M | 9.90M | 46.59M | 50.31M |
| Total Liabilities | 357.78M | 517.84M | 138.33M | 400.24M | 135.23M |
| Stockholders Equity | 941.78M | 1.05B | 796.47M | 705.13M | 533.48M |
Cash Flow | |||||
| Free Cash Flow | -362.10M | -317.57M | -166.95M | -176.79M | -226.17M |
| Operating Cash Flow | -343.91M | -295.54M | -162.62M | -164.60M | -197.33M |
| Investing Cash Flow | -60.92M | 22.63M | 275.95M | -157.21M | -77.24M |
| Financing Cash Flow | 661.55M | 722.37M | 254.84M | 351.71M | 9.95M |
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H Technical Analysis
Negative
7.10
Price Trends
3.72
Negative
5.64
Negative
13.61
Negative
Market Momentum
-0.20
Negative
43.08
Neutral
28.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2591, the sentiment is Negative. The current price of 7.1 is above the 20-day moving average (MA) of 3.52, above the 50-day MA of 3.72, and below the 200-day MA of 13.61, indicating a bearish trend. The MACD of -0.20 indicates Negative momentum. The RSI at 43.08 is Neutral, neither overbought nor oversold. The STOCH value of 28.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2591.
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$51.82B | 7.90 | 105.60% | ― | 292.84% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | HK$3.62B | 6.01 | 47.76% | ― | 286.20% | ― | |
50 Neutral | HK$10.12B | -5.93 | -153.78% | ― | 70.26% | -12.79% | |
48 Neutral | HK$6.32B | -56.20 | -9.45% | ― | 68.12% | 81.84% | |
47 Neutral | HK$6.06B | -30.68 | -10.27% | ― | -31.77% | -177.01% | |
45 Neutral | HK$1.55B | -3.90 | -32.98% | ― | 182.60% | -48.01% |
* General Sector Average
HK:2591
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H
3.40
-27.26
-88.91%
HK:9966
Alphamab Oncology
6.22
-5.47
-46.79%
HK:9995
RemeGen Co. Ltd. Class H
64.85
-28.00
-30.16%
HK:1167
Jacobio Pharmaceuticals Group Co., Ltd.
4.60
-2.66
-36.64%
HK:2171
CARsgen Therapeutics Holdings Ltd.
10.63
-6.92
-39.43%
HK:6855
Ascentage Pharma Group International
27.20
-40.70
-59.94%
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H Corporate Events
Guangzhou Innogen Strengthens Commercial Leadership With New Vice President Appointment
Oct 19, 2026
Guangzhou Innogen Pharmaceutical Group Co., Ltd., a Hong Kong-listed pharmaceutical manufacturer, focuses on developing and commercialising drug products for both Chinese and international markets. The group’s governance structure combines e...
Guangzhou Innogen Pharma Announces Board Resignations and Strategy Committee Change
Oct 16, 2026
Guangzhou Innogen Pharmaceutical Group has announced the resignation of executive director and vice president Xu Wenjie, who also stepped down from the board’s strategy committee, and non-executive director Heng Lei, both effective 16 Octobe...
Guangzhou Innogen Sets Out Board Structure and Committee Roles
Oct 16, 2026
Guangzhou Innogen Pharmaceutical Group Co., Ltd. has detailed its current board composition, confirming a mix of executive, non-executive and independent non-executive directors, led by Chairman and general manager Dr. Wang Qinghua. The announceme...
Innogen Pharma Founder and Executives Extend Share Lock-Up to Signal Confidence
Sep 7, 2026
Guangzhou Innogen Pharmaceutical Group announced that its founder and chairman, Dr. Wang Qinghua, together with three executive directors and senior managers, have voluntarily agreed not to dispose of any of their directly or indirectly held share...
Guangzhou Innogen Pharmaceutical Launches HK$50 Million H-Share Buyback Plan
Aug 25, 2026
Guangzhou Innogen Pharmaceutical Group plans to repurchase up to approximately HK$50 million worth of H shares on the Hong Kong market under an existing shareholder-approved mandate between 26 August 2026 and its next annual general meeting. The r...
Innogen ramps Efsubaglutide push as losses persist in first NRDL year
Aug 25, 2026
Guangzhou Innogen Pharmaceutical Group reported interim unaudited results for the six months ended 30 June 2026, with revenue rising to RMB78.2 million from RMB56.4 million year-on-year, but the period remained loss-making with a net loss of RMB11...
Guangzhou Innogen Schedules Board Meeting to Review 2026 Interim Results and Dividend Plan
Aug 13, 2026
Guangzhou Innogen Pharmaceutical Group Co., Ltd. has scheduled a board meeting for 25 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The agenda also includes considering the publication of these result...
Guangzhou Innogen Gains PIC/S GMP Approval for Efsubaglutide Manufacturing Sites
Aug 3, 2026
Guangzhou Innogen Pharmaceutical Group announced that two China-based contract manufacturing sites for its Efsubaglutide Alfa injection have passed a Good Manufacturing Practice inspection by Brazil’s health regulator ANVISA under Pharmaceut...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.